During the last session, Jaguar Health Inc (NASDAQ:JAGX)’s traded shares were 0.74 million, with the beta value of the company hitting 0.84. At the end of the trading day, the stock’s price was $1.15, reflecting an intraday gain of 5.50% or $0.06. The 52-week high for the JAGX share is $21.60, that puts it down -1778.26 from that peak though still a striking 26.96% gain since the share price plummeted to a 52-week low of $0.84. The company’s market capitalization is $13.57M, and the average intraday trading volume over the past 10 days was 0.49 million shares, and the average trade volume was 371.03K shares over the past three months.
Jaguar Health Inc (JAGX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. JAGX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.74.
Jaguar Health Inc (NASDAQ:JAGX) trade information
Jaguar Health Inc (JAGX) registered a 5.50% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.50% in intraday trading to $1.15, hitting a weekly high. The stock’s 5-day price performance is 8.49%, and it has moved by 13.86% in 30 days. Based on these gigs, the overall price performance for the year is -86.54%. The short interest in Jaguar Health Inc (NASDAQ:JAGX) is 0.33 million shares and it means that shorts have 1.12 day(s) to cover.
Jaguar Health Inc (JAGX) estimates and forecasts
Statistics show that Jaguar Health Inc has outperformed its competitors in share price, compared to the industry in which it operates. Jaguar Health Inc (JAGX) shares have gone down -67.97% during the last six months, with a year-to-date growth rate more than the industry average at 99.26% against 16.60.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.13M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 3.29M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 86.10%. While earnings are projected to return 99.26% in 2025, the next five years will return 40.00% per annum.
JAGX Dividends
Jaguar Health Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Jaguar Health Inc (NASDAQ:JAGX)’s Major holders
Jaguar Health Inc insiders own 12.02% of total outstanding shares while institutional holders control 1.96%, with the float percentage being 2.22%.
